Business in the Burbs

Progenics shares rise on positive opinion

April

Shares of Progenics Pharmaceuticals Inc. surged $2.61, or 32.5 percent, today as the Eastview-based biotechnology company announced that regulators in Europe offered a positive opinion of a product candidate that would treat constipation in certain patients. Progenics and Wyeth Pharmaceuticals are seeking to develop and market the drug, called Relistor. The Committee for Medicinal Products for Human Use will send is opinion to the European Commission, the company said. Progenics shares closed at $10.64. Shares of Wyeth, which has a campus in Pearl River, rose 12 cents to close at $44.56.

This entry was posted on Thursday, April 24th, 2008 at 4:03 pm by Allan Drury. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Corporate doings

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.